A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HMPL-523 in Treatment of Primary Immune Thrombocytopenia (ITP) in Adults(ESLIM-01 Study)
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Sovleplenib (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Registrational; Therapeutic Use
- Acronyms ESLIM-01
- Sponsors HUTCHMED
- 22 Jul 2024 Last checked against ClinicalTrials.gov: US National Institutes of Health record.
- 16 Jul 2024 Planned End Date changed from 30 Dec 2023 to 30 Jun 2025.
- 16 Jul 2024 Planned primary completion date changed from 30 Dec 2023 to 30 Oct 2024.